CIAM
LCTX icon

Caitong International Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Caitong International Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59 Buy
45
+42
+1,400% +$58 ﹤0.01% 2319
2026
Q1 		$5 Buy
+3
New +$5 ﹤0.01% 2282

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Caitong International Asset Management's LCTX Position: Q2 2026 in Review

Caitong International Asset Management increased its Lineage Cell Therapeutics (LCTX) stake by 1,400% in Q2 2026, buying an estimated $58 and bringing the position to 45 shares worth $59. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

Caitong International Asset Management first reported a position in LCTX in Q1 2026 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Caitong International Asset Management held 45 shares of Lineage Cell Therapeutics worth $59 as of Q2 2026.
  • Caitong International Asset Management bought 42 Lineage Cell Therapeutics shares in Q2 2026, an estimated $58.
  • Lineage Cell Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2319 holding.
  • Caitong International Asset Management first reported a position in Lineage Cell Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.